Document is current
Any future updates will be listed below
-
Authors
Scott, Emma
Hodgson, Kirsty
Calle, Beatriz https://orcid.org/0000-0002-9893-9803
Turner, Helen
Cheung, Kathleen
Bermudez, Abel
Marques, Fernando Jose Garcia
Pye, Hayley https://orcid.org/0000-0001-7042-5416
Yo, Edward Christopher
Islam, Khirul
Oo, Htoo Zarni
McClurg, Urszula L.
Wilson, Laura
Thomas, Huw
Frame, Fiona M.
Orozco-Moreno, Margarita
Bastian, Kayla
Arredondo, Hector M.
Roustan, Chloe
Gray, Melissa Anne
Kelly, Lois
Tolson, Aaron
Mellor, Ellie
Hysenaj, Gerald
Goode, Emily Archer
Garnham, Rebecca
Duxfield, Adam
Heavey, Susan
Stopka-Farooqui, Urszula
Haider, Aiman
Freeman, Alex
Singh, Saurabh
Johnston, Edward W.
Punwani, Shonit
Knight, Bridget
McCullagh, Paul
McGrath, John
Crundwell, Malcolm
Harries, Lorna
Bogdan, Denisa
Westaby, Daniel
Fowler, Gemma
Flohr, Penny
Yuan, Wei
Sharp, Adam https://orcid.org/0000-0002-3740-1612
de Bono, Johann
Maitland, Norman J. https://orcid.org/0000-0003-1607-9035
Wisnovsky, Simon
Bertozzi, Carolyn R. https://orcid.org/0000-0003-4482-2754
Heer, Rakesh
Guerrero, Ramon Hurtado https://orcid.org/0000-0002-3122-9401
Daugaard, Mads
Leivo, Janne
Whitaker, Hayley https://orcid.org/0000-0002-2695-0202
Pitteri, Sharon https://orcid.org/0000-0002-3119-873X
Wang, Ning
Elliott, David J.
Schumann, Benjamin https://orcid.org/0000-0001-5504-0147
Munkley, Jennifer https://orcid.org/0000-0002-8631-4531
-
Funding
Funding for this research was provided by:
Prostate Cancer UK (RIA16-ST2-011, TLD-PF19-002)
J.G.W. Patterson Foundation
Prostate Cancer Research and The Mark Foundation
- License Information
-
More Information
Article History
Received: 22 September 2022
Revised: 16 January 2023
Accepted: 19 January 2023
First Online: 1 February 2023
Competing interests
: JM is shareholder and Scientific Advisor of GlycoScoreDx Ltd. ES and GH are shareholders of GlycoScoreDx Ltd. The authors have filed a patent relating to this work (GB Patent GB2,594,103). CRB is a cofounder and scientific advisory board member of Lycia Therapeutics, Palleon Pharmaceuticals, EnableBioscience, Redwood Biosciences (a subsidiary of Catalent), OliLux Bio, Grace Science LLC, and InterVenn Biosciences. The other authors declare no competing interests.
